AU2017266738B2 - Tri-segmented Pichinde viruses as vaccine vectors - Google Patents

Tri-segmented Pichinde viruses as vaccine vectors Download PDF

Info

Publication number
AU2017266738B2
AU2017266738B2 AU2017266738A AU2017266738A AU2017266738B2 AU 2017266738 B2 AU2017266738 B2 AU 2017266738B2 AU 2017266738 A AU2017266738 A AU 2017266738A AU 2017266738 A AU2017266738 A AU 2017266738A AU 2017266738 B2 AU2017266738 B2 AU 2017266738B2
Authority
AU
Australia
Prior art keywords
pichinde virus
orf
segment
tri
utr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017266738A
Other languages
English (en)
Other versions
AU2017266738A1 (en
Inventor
Weldi BONILLA
Klaus Orlinger
Daniel David PINSCHEWER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Basel
Gilead Sciences Inc
Original Assignee
University of Basel
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Basel, Gilead Sciences Inc filed Critical University of Basel
Publication of AU2017266738A1 publication Critical patent/AU2017266738A1/en
Application granted granted Critical
Publication of AU2017266738B2 publication Critical patent/AU2017266738B2/en
Priority to AU2023285703A priority Critical patent/AU2023285703A1/en
Assigned to GILEAD SCIENCES, INC., UNIVERSITÄT BASEL reassignment GILEAD SCIENCES, INC. Request for Assignment Assignors: HOOKIPA BIOTECH GMBH, UNIVERSITÄT BASEL
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017266738A 2016-05-18 2017-05-17 Tri-segmented Pichinde viruses as vaccine vectors Active AU2017266738B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023285703A AU2023285703A1 (en) 2016-05-18 2023-12-18 Tri-segmented Pichinde viruses as vaccine vectors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338400P 2016-05-18 2016-05-18
US62/338,400 2016-05-18
PCT/EP2017/061865 WO2017198726A1 (en) 2016-05-18 2017-05-17 Tri-segmented pichinde viruses as vaccine vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023285703A Division AU2023285703A1 (en) 2016-05-18 2023-12-18 Tri-segmented Pichinde viruses as vaccine vectors

Publications (2)

Publication Number Publication Date
AU2017266738A1 AU2017266738A1 (en) 2018-11-29
AU2017266738B2 true AU2017266738B2 (en) 2023-10-12

Family

ID=58800799

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017266738A Active AU2017266738B2 (en) 2016-05-18 2017-05-17 Tri-segmented Pichinde viruses as vaccine vectors
AU2023285703A Abandoned AU2023285703A1 (en) 2016-05-18 2023-12-18 Tri-segmented Pichinde viruses as vaccine vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023285703A Abandoned AU2023285703A1 (en) 2016-05-18 2023-12-18 Tri-segmented Pichinde viruses as vaccine vectors

Country Status (12)

Country Link
US (3) US20190135875A1 (enExample)
EP (1) EP3458593A1 (enExample)
JP (3) JP7254018B2 (enExample)
KR (2) KR20240095333A (enExample)
CN (2) CN117486979A (enExample)
AU (2) AU2017266738B2 (enExample)
CA (1) CA3023599A1 (enExample)
EA (1) EA201892648A1 (enExample)
IL (2) IL262963B2 (enExample)
MX (2) MX2018013956A (enExample)
SG (1) SG11201810048VA (enExample)
WO (1) WO2017198726A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN114981443A (zh) 2019-11-07 2022-08-30 巴塞尔大学 作为载体的沙粒病毒
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
MX2023011054A (es) 2021-03-23 2023-11-22 Hookipa Biotech Gmbh Arenavirus utilizados en tratamientos del cáncer de próstata.
EP4337320A1 (en) 2021-05-13 2024-03-20 Hookipa Biotech GmbH Arenaviruses as vectors
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022269362A2 (en) * 2021-06-21 2022-12-29 Vaxxinova International B.V. Veterinary viral vector
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20250073324A1 (en) 2021-11-08 2025-03-06 Hookipa Biotech Gmbh Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
WO2016048949A1 (en) * 2014-09-22 2016-03-31 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
US9809801B2 (en) * 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
CN103224999B (zh) * 2013-04-25 2015-11-18 中华人民共和国大榭出入境检验检疫局 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
WO2016048949A1 (en) * 2014-09-22 2016-03-31 Regents Of The University Of Minnesota Pichinde virus reverse genetics system and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DHANWANI R et al., ‘A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose’, JOURNAL OF VIROLOGY. (2016), vol. 90, no. 5, pages 2551-2560. *

Also Published As

Publication number Publication date
NZ748120A (en) 2025-08-29
MX2024005757A (es) 2024-05-24
US20190135875A1 (en) 2019-05-09
AU2017266738A1 (en) 2018-11-29
JP2019516410A (ja) 2019-06-20
IL262963A (en) 2018-12-31
CA3023599A1 (en) 2017-11-23
JP2023012463A (ja) 2023-01-25
EP3458593A1 (en) 2019-03-27
CN109804074A (zh) 2019-05-24
EA201892648A1 (ru) 2019-06-28
NZ788311A (en) 2025-11-28
WO2017198726A1 (en) 2017-11-23
SG11201810048VA (en) 2018-12-28
KR102671785B1 (ko) 2024-06-04
JP7547433B2 (ja) 2024-09-09
AU2023285703A1 (en) 2024-01-18
MX2018013956A (es) 2019-07-04
US20220289797A1 (en) 2022-09-15
BR112018073794A2 (pt) 2019-02-26
CN109804074B (zh) 2023-10-10
IL262963B2 (en) 2025-01-01
US20260109736A1 (en) 2026-04-23
IL262963B1 (en) 2024-09-01
JP7254018B2 (ja) 2023-04-07
KR20190016032A (ko) 2019-02-15
JP2024170461A (ja) 2024-12-10
IL314272A (en) 2024-09-01
CN117486979A (zh) 2024-02-02
KR20240095333A (ko) 2024-06-25

Similar Documents

Publication Publication Date Title
US20260109736A1 (en) Tri-segmented pichinde viruses as vaccine vectors
US20240082376A1 (en) Tri-segmented arenaviruses as vaccine vectors
HK40036451A (en) Tri-segmented arenaviruses as vaccine vectors
HK40036451B (en) Tri-segmented arenaviruses as vaccine vectors
HK40004707A (zh) 作为疫苗载体的三区段pichinde病毒
HK40004707B (en) Tri-segmented pichinde viruses as vaccine vectors
EA046869B1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин
HK1244034B (en) Tri-segmented arenaviruses as vaccine vectors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: UNIVERSITAET BASEL

Free format text: FORMER OWNER(S): UNIVERSITAET BASEL; HOOKIPA BIOTECH GMBH

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER(S): UNIVERSITAET BASEL; HOOKIPA BIOTECH GMBH